Insider Selling: Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Sells $24,974.40 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRXGet Free Report) Director Paul J. Hastings sold 880 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total transaction of $24,974.40. Following the completion of the transaction, the director now directly owns 12,724 shares of the company’s stock, valued at $361,107.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pacira BioSciences Stock Down 0.8 %

Pacira BioSciences stock opened at $28.13 on Friday. The business’s 50-day moving average price is $28.52 and its 200 day moving average price is $29.84. The company has a quick ratio of 4.78, a current ratio of 5.81 and a debt-to-equity ratio of 0.57. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of 19.67 and a beta of 0.87. Pacira BioSciences, Inc. has a 52 week low of $25.33 and a 52 week high of $41.65.

Pacira BioSciences (NASDAQ:PCRXGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The firm had revenue of $167.12 million for the quarter, compared to analyst estimates of $165.43 million. Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.13 earnings per share for the current year.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $40,488,000. Pacer Advisors Inc. grew its holdings in Pacira BioSciences by 397,487.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,041,679 shares of the company’s stock valued at $35,146,000 after purchasing an additional 1,041,417 shares during the period. Archon Capital Management LLC purchased a new stake in shares of Pacira BioSciences in the first quarter valued at approximately $15,677,000. Rubric Capital Management LP acquired a new position in Pacira BioSciences during the third quarter worth $14,102,000. Finally, Frontier Capital Management Co. LLC lifted its holdings in Pacira BioSciences by 15.8% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock valued at $70,332,000 after purchasing an additional 285,045 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PCRX shares. Barclays decreased their price target on shares of Pacira BioSciences from $40.00 to $38.00 and set an “overweight” rating for the company in a report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Pacira BioSciences in a research note on Wednesday, May 8th. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a research note on Thursday, March 7th. They set an “overweight” rating and a $45.00 price target on the stock. TheStreet upgraded Pacira BioSciences from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC decreased their target price on Pacira BioSciences from $45.00 to $43.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Eleven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $47.40.

Read Our Latest Research Report on Pacira BioSciences

Pacira BioSciences Company Profile

(Get Free Report)

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.

Read More

Insider Buying and Selling by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.